Inhibition of the LIF/LIFR/JAK1 pathway or inhibition of BRD4, which increases LIFR transcription, increases sensitivity of breast cancer cell lines, xenografts, and allografts to histone deacetylase inhibitors [61]. Here, LIFR is linked to breast cancer.